Search
Heart failure (HF) is the end stage of most cardiovascular diseases and remains a significant health problem globally. We aimed to assess whether patients with left ventricular ejection fraction ≤45% had alterations in both the gut microbiome profile and production of associated metabolites when compared to a healthy cohort.
Cystic fibrosis (CF) airway disease is characterized by chronic inflammation, featuring neutrophil influx to the lumen. Airway macrophages (AMs) can promote both inflammation and resolution, and are thus critical to maintaining and restoring homeostasis. CF AM functions, specifically scavenging activity and resolution of inflammation, have been shown to be impaired, yet underlying processes remain unknown.
Allergic sensitization and reduced ability to respond to viral infections may contribute to virus-induced wheeze and asthma development in young children. Plasmacytoid dendritic cells (pDC) are rare immune cells that produce type I interferons (IFN-I) and play a key role in orchestrating immune responses against viruses.
Rising carbon dioxide levels are being detected within the human body, with new research warning a key blood marker for the gas could near its healthy limit within decades if current trends continue.
Researchers developing a world-first treatment that targets an underlying cause of asthma have secured a $499,640 grant from the Future Health, Research and Innovation Fund – Innovation Seed Fund.
Dr Renee Ng, a microbiologist specialising in bacteriophage therapy – an alternative to antibiotics to fight antimicrobial resistance – will travel to the world’s premier conference on viruses, bringing new ideas, connections and expertise back to Perth.
New hope is on the horizon for people living with cystic fibrosis.
A ground-breaking global clinical trial to improve the lifelong lung health of children born extremely prematurely has been awarded a Medical Research Future Fund (MRFF) International Clinical Trials Collaborations Grant totalling almost $3 million.
Respiratory disease remains one of the most significant complications of preterm birth, with lasting consequences.
Wal-yan researchers have been awarded $500,000 for their innovative research, supported by the Western Australian Government’s Future Health Medical Research and Innovation (FHRI) Fund.